diabetes management algorithm step 2 medicine shelf glyburide semaglutide The pharmacological of Type Diabetes, adapted from ADA 2025 guidelines, focusing on treatment initiation and intensification based on patient comorbidities and glycemic control Type 2 diabetes treatment guidelines

Contraindications:: Patients with a personal or family history of medullary thyroid carcinoma (based upon animal data - see FDA Warning) History of hypersensitivity to semaglutide or any of its excipients (serious reactions including angioedema & anaphylaxis have been reported) Side Effects: GI Adverse events: nausea, vomiting, constipation, diarrhea (~5-15%) most GI side side effects occur during dose initiation or escalation and wane after a few weeks (Drucker, 2024)

Patients on the 7.2 mg weekly dose achieved an average weight loss of 20.7% of starting body weight over 72 weeks, compared to 17.5% at the standard 2.4 mg dose

View More 04 Jun You may notice your face seems more tired, hollow, or less defined than it used to be

Participants lost an average of nearly 15% of their initial body weight

All treatment types must be available to patients

Pharmaceuticals (Basel, Switzerland), 14(6), 515